Cell Therapy Meets Biologics: BriaCell’s Dual-Track Oncology Push

PHILADELPHIA – November 03, 2026

In the high-stakes arena of immuno-oncology, the low-hanging fruit was harvested years ago. The first generation of checkpoint inhibitors revolutionized cancer care, but their efficacy has largely been confined to "hot" tumors with high mutational burdens. The 21st-century marketplace for oncology therapeutics is now defined by the race to crack "cold" solid tumors—a challenge that has repeatedly thwarted single-agent approaches.

To survive in this next phase of the biotechnology arms race, companies are being forced to rethink their structural approach to pipeline development. BriaCell Therapeutics is emerging as a fascinating case study in this strategic pivot. Today, the clinical-stage biotech and its majority-owned subsidiary, BriaPro Therapeutics, announced a slate of four preclinical presentations for the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.

The data, spanning both cellular vaccines and engineered fusion proteins, illustrates a deliberate "dual-track" strategy: developing off-the-shelf cell therapies to prime the immune system, while simultaneously engineering novel biologics to micromanage the complex microenvironment of solid tumors.

Beyond Breast Cancer: The Bria-OTS+ Evolution

BriaCell’s foundational technology relies on activating a patient's innate and adaptive immune systems using genetically engineered whole-cell vaccines. Its lead clinical candidate, Bria-IMT, is currently navigating a pivotal Phase 3 trial for metastatic breast cancer—a study notable enough to be highlighted by Nature Medicine as one of the clinical trials poised to shape medicine in 2026.

However, the SITC presentations signal a strategic expansion beyond breast cancer via the company's third-generation platform, Bria-OTS+. Where early autologous cell therapies were hampered by agonizingly slow manufacturing times and exorbitant costs, the "off-the-shelf" (allogeneic) model represents the future of commercial viability in cell therapy. Bria-OTS+ utilizes partial HLA matching for tumor-antigen presentation, deliberately paired with planned HLA mismatching designed to drive robust CD4+ helper T-cell responses.

According to the newly released abstracts, in vitro studies of Bria-OTS+ demonstrated broad tumor recognition, sustained cytotoxicity, and memory-like immune responses across breast, prostate, and lung cancer models. Furthermore, the platform successfully induced immune activation in peripheral blood mononuclear cells (PBMCs) obtained directly from cancer patients, a critical step in validating the translatability of these laboratory findings.

"The Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing in laboratory models spanning breast, prostate and lung cancers," said Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. "These findings support continued investigation of the platform, including how its immune responses may translate into clinical activity, potentially providing more durable and effective cancer immunotherapies."

For industry analysts, the expansion into prostate and lung indications is the critical takeaway. By proving the modularity of the Bria-OTS+ platform, BriaCell is attempting to transition from a niche breast cancer player into a broad-spectrum solid tumor contender. The company is reportedly aiming to enter the clinic with Bria-OTS+ for metastatic breast and prostate cancers by late 2026, backed in part by a $2 million National Cancer Institute award for the prostate program.

Engineering CD80: Uncoupling Co-Stimulation from Toxicity

While BriaCell pushes its cellular therapies forward, its subsidiary BriaPro is taking a structural biology approach to the B7/CD28/CTLA-4 immune axis. This pathway is the master switchboard of T-cell activation, but it is notoriously difficult to drug. Historical attempts to aggressively stimulate CD28 have resulted in catastrophic toxicities, forcing drug developers to walk a razor-thin line between efficacy and fatal immune overdrive.

BriaPro’s strategy centers on engineering the CD80 protein to uncouple these effects. Wild-type CD80 naturally binds to both CD28 (providing a "go" signal to T-cells) and CTLA-4 (providing a "stop" signal), while also interacting with PD-L1. Through structure-guided protein engineering, BriaPro has developed CD80 variants with radically altered affinities. One variant highlighted in the SITC abstracts boasts a more than 130-fold stronger binding affinity for PD-L1 compared to wild-type CD80, while preserving its standard affinity for CD28.

By selectively amplifying PD-L1 binding, BriaPro is essentially repurposing CD80 to act as a highly potent, targeted checkpoint modulator. This could allow for fine-tuned T-cell co-stimulation without triggering the systemic cytokine storms associated with broad CD28 agonists.

The subsidiary is also advancing TILsRx-001, a tetravalent bispecific checkpoint inhibitor targeting both B7-H3 and PD-L1. B7-H3 is a highly sought-after target in oncology right now, frequently overexpressed in solid tumors and associated with poor prognoses. By physically linking B7-H3 targeting with PD-L1 blockade, TILsRx-001 aims to reactivate tumor-infiltrating lymphocytes (TILs) directly at the site of the malignancy, stripping the tumor of two distinct immunosuppressive shields simultaneously.

Equally noteworthy is the preclinical pharmacokinetic data for BP-80, BriaPro’s soluble CD80-Fc fusion protein. In nonhuman primates, BP-80 demonstrated a remarkably high "no observed effect level" (NOEL) of 50 mg/kg/day. As one independent preclinical pharmacologist noted, achieving a NOEL of this magnitude for an immune-modulating biologic suggests an exceptionally wide therapeutic window and a highly favorable acute safety profile.

However, the data also revealed an elimination half-life of roughly 8.5 hours—unusually short for an Fc-fusion protein, which typically circulates for days or weeks. From a commercial and clinical design standpoint, this short half-life presents a strategic puzzle. It will likely necessitate frequent dosing, which can increase the cost of goods sold and impact patient adherence. Conversely, in the volatile realm of immune agonists, a rapid clearance rate can act as a built-in safety switch, allowing clinicians to quickly halt exposure if adverse events occur.

The Strategic Rationale of a Dual-Track Pipeline

Operating a sprawling Phase 3 clinical cell therapy program alongside a cutting-edge protein engineering subsidiary requires immense capital. BriaCell reported a net loss of $35.3 million for the fiscal year 2026, driven largely by a 37.5 percent surge in research and development costs. The pivotal Phase 3 Bria-IMT study alone consumed $16.5 million.

Despite raising $4.7 million in a June 2026 offering, the company’s cash burn reflects the stark reality of late-stage oncology development. So, why maintain the dual-track strategy? Why not spin off BriaPro or shelve the preclinical biologics to conserve runway for the Phase 3 trial?

The answer lies in the shifting paradigm of cancer treatment and corporate risk mitigation. "The four presentations provide additional preclinical data supporting our cellular and protein-based immunotherapy research," stated William V. Williams, MD, BriaCell’s President and CEO. "We are advancing the clinical evaluation of our Bria-OTS+ programs while continuing preclinical development of BriaPro’s candidates."

From a strategic perspective, BriaCell is building a modular toolkit. Cellular vaccines like Bria-OTS+ are designed to educate the immune system and drive T-cells into the tumor bed. But once those T-cells arrive, they often face a hostile, immunosuppressive microenvironment. BriaPro’s engineered CD80 variants and bispecific inhibitors are being designed precisely to dismantle that local suppression.

By keeping both technologies under one corporate umbrella, BriaCell retains the optionality to eventually combine them—pairing a proprietary off-the-shelf vaccine with a proprietary checkpoint modulator. In a marketplace where combination therapies are the gold standard, owning both halves of the equation provides immense pricing power and protects against the margin-crushing reality of having to license a partner's blockbuster checkpoint inhibitor.

Furthermore, BriaPro functions as a strategic hedge. If the cellular therapy arm faces regulatory hurdles, the protein engineering pipeline offers a distinct, highly attractive asset class for potential out-licensing or acquisition by larger pharmaceutical companies hungry for novel bispecifics.

As the SITC 2026 presentations will demonstrate, BriaCell is not just trying to build a better breast cancer drug. By expanding into new solid tumors with Bria-OTS+ and rewriting the binding affinities of CD80 through BriaPro, the company is attempting to engineer a structural advantage in one of the most unforgiving therapeutic landscapes in modern medicine.